CS02 vs Placebo With Metformin in Type 2 Diabetic Subjects

T2DM With Inadequate Glycemic Control Clinical Trial

Official title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With T2DM Who Have Inadequate Glycemic Control on Metformin Alone

Status Recruiting

Clinical Trial Summary

The objective of the study is to compare the efficacy and safety of 3 doses CS02 Tablet in combination with a stable dose of metformin monotherapy against CS02 PTM (placebo) Tablet in combination with a stable dose of metformin monotherapy over a 12 weeks treatment period in subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin alone.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• T2DM With Inadequate Glycemic Control

• NCT number: NCT03308695
• Study type: Interventional
• Source: Center Laboratories, Inc.
• Contact: Eric Shane
• Phone: +886-2-2655 8680
• Email: eric_shane@centerlab.comtw
• Status: Recruiting
• Phase: Phase 2
• Start date: October 1, 2017
• Completion date: May 31, 2021